Future studies addressing this gap could provide valuable insights into the underlying mechanisms and further substantiate the therapeutic potential of miltefosine in treating thrombocytopenia, particularly in CCR5-targeted therapies. The gene discussed is CCR5; the disease is Thrombocytopenia.